Hutchmed (China) Ltd., a cancer drug developer backed by billionaire Li Ka-shing, jumped in its first day of trade in Hong Kong about two years after it delayed a previous attempt to list in the city. Shares of the biopharmaceutical company that already trades in the U.S. and the U.K. opened at HK$51.40 on Wednesday, up 28% from their offer price of HK$40.10. Hutchmed raised $537 million in the offering.
https://www.bloombergquint.com/markets/china-cancer-drugmaker-surges-28-in-hong-kong-trading-debut
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.